Latest Breaking News On - அவசரம் அறுவை சிகிச்சை - Page 1 : comparemela.com

Posted on 354 Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the fourth quarter and full year of 2020. Total revenues for the full year of 2020 were $6,069.9 million, a 22 percent increase compared to the same period in 2019. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $52.0 million, inclusive of hedging activities. On a GAAP basis, diluted EPS for the full year of 2020 was $2.72, compared to $10.70 in the prior year. Full year 2020 includes impairment charges of $2,053.3 million primarily relating to the KANUMA intangible asset and a related deferred tax benefit of $377.3 million. Full year 2019 includes one-time tax benefits of $382.2 million related to intra-entity asset transfers of intellectual property. Non-GAAP diluted EPS for the full year of 2020 was $12.51, a 19 percent increase versus the prior year.

New zealandUnited statesUnited kingdomInozyme pharmaCaelum biosciencesLudwig hantsonMegan goulartAsia pacificZealand pharmaAstrazeneca investor relations departmentAchillion pharmaceuticals incStealth biotherapeutics corpUs national institute of allergyJapan ministry of healthPharmaceuticals immune pharmaCambridge university hospitals